期刊
PHARMACEUTICALS
卷 14, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/ph14121337
关键词
osteoarthritis; chondrocyte hypertrophy; licorice; Wongam
资金
- Cooperative Research Program for Agriculture Science and Technology Development Rural Development Administration, Republic of Korea [PJ01424602]
This study investigated the regulatory effect of Glycyrrhiza new variety, Wongam (WG), on chondrocyte hypertrophy-like changes induced by IL-1 beta. The results showed that WG could inhibit chondrocyte hypertrophy by targeting HDAC4 activation and the SOX9/beta-catenin signaling pathway. In silico analysis revealed that licorice contains 21 active compounds that can bind to 11 targets related to chondrocyte hypertrophy.
Osteoarthritis (OA) is a common degenerative joint disorder that affects joint function, mobility, and pain. The release of proinflammatory cytokines stimulates matrix metalloproteinases (MMPs) and aggrecanase production which further induces articular cartilage degradation. Hypertrophy-like changes in chondrocytes are considered to be an important feature of OA pathogenesis. A Glycyrrhiza new variety, Wongam (WG), was developed by the Korea Rural Development Administration to enhance the cultivation and quality of Glycyrrhizae Radix et Rhizoma (licorice). This study examined the regulatory effect of WG against hypertrophy-like changes such as RUNX2, Collagen X, VEGFA, MMP-13 induction, and Collagen II reduction induced by IL-1 beta in SW1353 human chondrocytes. Additionally, in silico methods were performed to identify active compounds in licorice to target chondrocyte hypertrophy-related proteins. WG showed inhibitory effects against IL-1 beta-induced chondrocyte hypertrophy by regulating both HDAC4 activation via the PTH1R/PKA/PP2A pathway and the SOX9/beta-catenin signaling pathway. In silico analysis demonstrated that 21 active compounds from licorice have binding potential with 11 targets related to chondrocyte hypertrophy. Further molecular docking analysis and in vivo studies elicited four compounds. Based on HPLC, isoliquiritigenin and its precursors were identified and quantified. Taken together, WG is a potential therapeutic agent for chondrocyte hypertrophy-like changes in OA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据